How 2025 U.S. Tariffs Are Reshaping Global Pharma Supply Chains

In this episode, we dive deep into how rising U.S. tariffs on pharmaceutical imports—from APIs and drug intermediates to packaging and manufacturing equipment—are transforming the industry. With 20–25% duties on imports from China and India, pharma manufacturers are facing surging costs, disrupted supply chains, and longer production timelines. We unpack the sector-wise impact on generics, biologics, vaccines, and CMOs, and explore how companies are responding through nearshoring, regulatory navigation, and data-driven decision-making. Discover how market research is evolving from a background tool to a front-line defense in safeguarding resilience, cost-efficiency, and therapeutic continuity.